尊龙凯时·「中国区」官方网站

2024-01-19 Grand Pharma’s Coronary Imaging Device for Intracavity Diagnosis NOVASIGHT Achieves First Clinical Application

2024-01-19 The Phase II Clinical Study of Grand Pharma’s Global Innovative Product STC3141 Has Completed the First Patient Enrollment and Dosing in China

2023-11-21 The Launch of “the Liver Cancer Assistance Yttrium Little Red Flower Health Fund Project”: Low-income Patients Eligible for Financial Assistance

2023-11-16 Bi-Monthly Progress Snapshot of Grand Pharma (September-October)

2023-11-16 力美通® (Limeitong) Eplerenone Tablets Officially Launched National Academic Tour

2023-11-16 First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

2023-11-16 Grand Pharma’s Global Innovative Therapeutic Tumor Vaccine ARC01 China Clinical Trial Application Accepted

2023-10-11 Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry

2023-08-09 World’s First Novasight Dual-Mode Intravascular Imaging Catheter Obtained the Import Drug License in China

2023-08-07 Grand Pharmaceutical Group Has Been Selected as a National Talent Introduction Platform

2023-08-07 Grand Pharmaceutical Group’s New MRA Drug Eplerenone Tablets Obtained the Drug License

2021-11-28 GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn